|
|
Exchange: |
N/A |
Security
Type: |
Common |
Shares
Out: |
15,090,000 |
Market
Cap: |
33.20(K) |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$0 - $5.76 |
|
Level
I Sector: |
N/A |
Level
II Sector: |
N/A |
Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Ampio Pharmaceuticals is a biopharmaceutical company focused on the research, development and improvement of immunomodulatory therapies for the treatment of pain from osteoarthritis. Ampion, Co.'s primary product candidate is a biologic drug, which contains ingredients that target several pathways in the innate immune response characteristic of inflammatory disease. Ampion is in development as an intra-articular injection treatment for severe Osteoarthritis of the Knee; an intravenous and inhaled treatment for COVID-19 patients; and an at-home inhalation treatment for patients with prolonged respiratory symptoms due to COVID-19.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
318,748 |
Total Buy Value |
$0 |
$0 |
$0 |
$81,874 |
Total People Bought |
0 |
0 |
0 |
3 |
Total Buy Transactions |
0 |
0 |
0 |
8 |
Total Shares Sold |
0 |
0 |
0 |
0 |
Total Sell Value |
$0 |
$0 |
$0 |
$0 |
Total People Sold |
0 |
0 |
0 |
0 |
Total Sell Transactions |
0 |
0 |
0 |
0 |
End Date |
2024-06-27 |
2024-03-26 |
2023-09-26 |
2022-09-26 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Coelho Philip H |
Director |
|
2017-09-27 |
4 |
B |
$0.63 |
$6,270 |
D/D |
10,000 |
104,727 |
2.39 |
- |
|
Coelho Philip H |
Director |
|
2017-09-22 |
4 |
B |
$0.60 |
$1,800 |
D/D |
3,000 |
94,727 |
2.31 |
- |
|
Coelho Philip H |
Director |
|
2017-09-20 |
4 |
B |
$0.59 |
$592 |
D/D |
1,000 |
91,727 |
2.31 |
- |
|
Coelho Philip H |
Director |
|
2017-09-19 |
4 |
B |
$0.57 |
$8,519 |
D/D |
15,000 |
90,727 |
2.39 |
- |
|
Coelho Philip H |
Director |
|
2017-09-05 |
4/A |
B |
$0.56 |
$16,776 |
D/D |
30,000 |
75,727 |
2.39 |
- |
|
Coelho Philip H |
Director |
|
2017-09-05 |
4 |
S |
$0.56 |
$16,776 |
D/D |
(30,000) |
75,727 |
|
- |
|
Coelho Philip H |
Director |
|
2017-01-03 |
4 |
A |
$0.96 |
$19,999 |
D/D |
20,826 |
45,727 |
|
- |
|
Stevens David R |
Director |
|
2017-01-03 |
4 |
A |
$0.96 |
$19,999 |
D/D |
20,826 |
35,789 |
|
- |
|
Giles Richard B |
Director |
|
2017-01-03 |
4 |
A |
$0.96 |
$19,999 |
D/D |
20,826 |
216,093 |
|
- |
|
Stevens David R |
Director |
|
2016-01-04 |
4 |
A |
$3.31 |
$19,999 |
D/D |
6,042 |
14,963 |
|
- |
|
Coelho Philip H |
Director |
|
2016-01-04 |
4 |
A |
$3.31 |
$19,999 |
D/D |
6,042 |
24,901 |
|
- |
|
Stevens David R |
Director |
|
2015-01-02 |
4 |
A |
$3.75 |
$9,998 |
D/D |
2,666 |
8,921 |
|
- |
|
Giles Richard B |
Director |
|
2015-01-02 |
4 |
A |
$3.75 |
$9,998 |
D/D |
2,666 |
189,225 |
|
- |
|
Coelho Philip H |
Director |
|
2015-01-02 |
4 |
A |
$3.75 |
$9,998 |
D/D |
2,666 |
18,859 |
|
- |
|
Clift Vaughan Lennox |
Chief Regulatory Affairs |
|
2014-02-25 |
5 |
D |
$8.02 |
$4,188,044 |
D/D |
(522,200) |
0 |
|
- |
|
Giles Richard B |
Director |
|
2014-01-02 |
4 |
A |
$7.13 |
$10,003 |
D/D |
1,403 |
186,559 |
|
- |
|
Coelho Philip H |
Director |
|
2014-01-02 |
4 |
A |
$7.13 |
$10,003 |
D/D |
1,403 |
16,193 |
|
- |
|
Stevens David R |
Director |
|
2014-01-02 |
4 |
A |
$7.13 |
$10,003 |
D/D |
1,403 |
6,255 |
|
- |
|
Giles Richard B |
Director |
|
2013-12-03 |
4 |
OE |
$1.75 |
$20,857 |
D/D |
11,918 |
185,156 |
|
- |
|
Macaluso Michael |
Chief Executive Officer |
|
2013-11-27 |
4 |
OE |
$1.75 |
$47,913 |
D/D |
27,379 |
1,786,752 |
|
- |
|
Coelho Philip H |
Director |
|
2013-11-18 |
4 |
S |
$8.25 |
$109,666 |
D/D |
(13,287) |
14,790 |
|
- |
|
Coelho Philip H |
Director |
|
2013-11-15 |
4 |
S |
$8.22 |
$93,070 |
D/D |
(11,320) |
28,077 |
|
- |
|
Bar-Or David |
Chief Scientific Officer |
|
2013-11-11 |
4 |
GD |
$0.00 |
$0 |
D/D |
2,700,000 |
0 |
|
- |
|
Macaluso Michael |
Chief Executive Officer |
|
2013-10-01 |
4 |
GD |
$0.00 |
$0 |
D/D |
284,000 |
1,759,373 |
|
- |
|
Giles Richard B |
Director |
|
2013-01-18 |
4 |
OE |
$2.20 |
$116,751 |
I/I |
50,417 |
50,417 |
|
- |
|
93 Records found
|
|
Page 3 of 4 |
|
|